Related Experiment Video
Updated: Sep 8, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase
Hui Li1, Kaiyan Chen1, Lei Gong1
1Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Importance:
Central nervous system (CNS) metastases remain a significant challenge in the management of EGFR-variant non-small cell lung cancer (NSCLC).
Objective:
To evaluate the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant NSCLC and brain metastases.
Design, Setting, And Participants:
This was a phase 2 nonrandomized clinical trial conducted at 10 centers in China. Patients with untreated EGFR-variant metastatic NSCLC and brain metastases were enrolled between July 6, 2021, and August 31, 2022. The data cutoff date was October 10, 2024.
Interventions:
Patients received aumolertinib, 165 mg, orally once daily until disease progression or unacceptable toxic effects.
Main Outcomes And Measures:
The primary end point was 12-month progression-free survival (PFS) rate assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1.
Results:
A total of 63 patients (39 female [61.9%]; median age, 60 [range, 47-76] years) were enrolled (full analysis set), and 49 had at least 1 measurable brain lesion (CNS evaluable-for-response set). Median follow-up duration was 28.8 months (95% CI, 27.0-29.8). In the full analysis set, the 12-month PFS rate was 62.1% (95% CI, 48.7-73.0), the median PFS was 20.5 months (95% CI, 12.0-26.9), the 12-month intracranial PFS rate was 76.8% (95% CI, 63.2-85.9), and the median intracranial PFS and overall survival were not reached. Systemic and intracranial objective response rates per RECIST 1.1 were 56 of 63 (88.9% [95% CI, 78.4-95.4]) and 52 of 63 (82.5% [95% CI, 70.9-90.9]) in the full analysis set and 43 of 49 (87.8% [95% CI, 75.2-95.4]) and 42 of 49 (85.7% [95% CI, 72.8-94.1]) in the CNS evaluable-for-response set, respectively. The most common grade 3 or 4 treatment-related adverse event was increased blood creatine phosphokinase (17 participants [27.0%]). No treatment-related deaths occurred. EGFR variant clearance in plasma circulating tumor DNA at day 1 of cycle 2 was independently associated with longer PFS (hazard ratio, 0.14 [95% CI, 0.04-0.47]; P = .001).
Conclusions And Relevance:
The findings of this nonrandomized clinical trial suggest that high-dose aumolertinib is associated with long-term survival benefit in patients with untreated EGFR-variant NSCLC and brain metastases, with a manageable safety profile.
Trial Registration:
ClinicalTrials.gov Identifier: NCT04808752.
Insights
High-dose aumolertinib shows promise for treating EGFR-variant non-small cell lung cancer (NSCLC) with brain metastases. This study indicates a significant survival benefit and manageable safety profile for patients with this challenging condition.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Central nervous system (CNS) metastases are a major challenge in EGFR-variant non-small cell lung cancer (NSCLC) management.
- Effective treatment strategies for NSCLC with brain metastases are urgently needed.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose aumolertinib in patients with untreated EGFR-variant NSCLC and brain metastases.
- To assess the progression-free survival (PFS) and objective response rates (ORR) in this patient population.
Main Methods:
- A phase 2, nonrandomized clinical trial involving 63 patients with untreated EGFR-variant metastatic NSCLC and brain metastases.
- Patients received aumolertinib 165 mg orally once daily until disease progression or unacceptable toxicity.
- The primary endpoint was the 12-month PFS rate, with secondary endpoints including ORR and safety.
Main Results:
- The 12-month PFS rate was 62.1%, with a median PFS of 20.5 months.
- Systemic and intracranial objective response rates were 88.9% and 85.7%, respectively.
- The most common grade 3/4 adverse event was increased blood creatine phosphokinase (27.0%); no treatment-related deaths occurred.
Conclusions:
- High-dose aumolertinib demonstrates a long-term survival benefit for patients with untreated EGFR-variant NSCLC and brain metastases.
- The drug exhibits a manageable safety profile, suggesting its potential as a valuable treatment option.
- EGFR variant clearance in circulating tumor DNA was associated with improved PFS.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
